The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.
 
Amer Methqal Zeidan
Honoraria - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Consulting or Advisory Role - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; Astex Pharmaceuticals; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Research Funding - Abbvie (Inst); Amgen; Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Geron; Kura Oncology; Novartis (Inst); Otsuka; Shattuck Labs; Syros Pharmaceuticals; Takeda (Inst)
 
Uwe Platzbecker
Honoraria - Abbvie; Celgene/Jazz; Curis; Geron; Janssen
Consulting or Advisory Role - BMS GmbH & Co. KG; Celgene/Jazz; Novartis
Research Funding - Amgen (Inst); BerGenBio (Inst); Celgene (Inst); Curis (Inst); Janssen (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - part of a patent for a TFR-2 antibody (Rauner et al. Nature Metabolics 2019)
Travel, Accommodations, Expenses - Celgene
 
Matteo Giovanni Della Porta
No Relationships to Disclose
 
Valeria Santini
Honoraria - Celgene/Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Abbvie; Celgene/Bristol-Myers Squibb; CTI; Curis; Geron; Gilead Sciences; Novartis; Otsuka; SERVIER; Syros Pharmaceuticals
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Celgene; Janssen-Cilag
 
Guillermo Garcia-Manero
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb/Celgene; Curis; Genentech; Gilead Sciences; Novartis
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb
Research Funding - Abbvie; Aprea Therapeutics; Astex Pharmaceuticals; Bristol-Myers Squibb; Curis; Genentech; Gilead Sciences; Novartis
 
Jiahui Li
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Sandra Kreitz
Employment - Bristol-Myers Squibb Stiftung Immunonkologie
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Veronika Pozharskaya
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Merck
 
Shelonitda Rose
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celgene
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Yinzhi Lai
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
David Valcárcel
Consulting or Advisory Role - Amgen; BMS; Celgene; GlaxoSmithKline; Jazz Pharmaceuticals; NOVARTIS; Pfizer; Sanofi; SOBI; Takeda
Speakers' Bureau - Amgen; Astellas Pharma; Astellas Pharma; BMS; Celgene; Gebro Pharma; GlaxoSmithKline; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis; Pfizer; Sanofi/Aventis
Travel, Accommodations, Expenses - Amgen; Celgene; GlaxoSmithKline; Jazz Pharmaceuticals; Pfizer
 
Pierre Fenaux
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
 
Jake Shortt
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Otsuka; Pfizer
Speakers' Bureau - Mundipharma; Novartis
Research Funding - Astex Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - WO/2017/059319/A3 (Inst); WO/2021/243421 (Inst)
 
Rami S. Komrokji
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; CTI BioPharma Corp; DSI; Geron; Gilead/Forty Seven; Jazz Pharmaceuticals; Novartis; Pharmaessentia; Sumitomo Pharma Oncology; Taiho Oncology; Takeda
Speakers' Bureau - Abbvie; CTI BioPharma Corp; Jazz Pharmaceuticals; Pharmaessentia; SERVIER
Research Funding - Bristol-Myers Squibb/Celgene (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Jazz Pharmaceuticals; Pharmaessentia